Outlook Therapeutics Inc
F:41O
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Outlook Therapeutics Inc
F:41O
|
US |
|
Medacta Group SA
SIX:MOVE
|
CH |
|
Ipsos SA
PAR:IPS
|
FR |
|
D
|
Dermapharm Holding SE
XMUN:DMP
|
DE |
|
Sofina SA
XBRU:SOF
|
BE |
|
Talisker Resources Ltd
TSX:TSK
|
CA |
|
S
|
Shell PLC
AEX:SHELL
|
UK |
|
Ipsos SA
OTC:IPSOF
|
FR |
|
C
|
Comp SA
WSE:CMP
|
PL |
|
Q
|
Qurate Retail Inc
F:LB3A
|
US |
|
Gerard Perrier Industrie SA
F:80T
|
FR |
|
K
|
Kforce Inc
F:ROF
|
US |
|
Korian SA
F:KO2
|
FR |
Wall St Price Targets
41O Price Targets Summary
Outlook Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for 41O is 3.72 EUR with a low forecast of 0.33 EUR and a high forecast of 6.96 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is 41O's stock price target?
Price Target
3.72
EUR
According to Wall Street analysts, the average 1-year price target for 41O is 3.72 EUR with a low forecast of 0.33 EUR and a high forecast of 6.96 EUR.
What is the Revenue forecast for Outlook Therapeutics Inc?
Projected CAGR
55%
Over the last 10 years, the compound annual growth rate for Revenue has been -12%. The projected CAGR for the next 8 years is 55%.
What is the Gross Profit forecast for Outlook Therapeutics Inc?
Projected CAGR
558%
The compound annual growth rate for Gross Profit over the next 3 years is 558%.
